[Thiazolidinediones for the treatment of type 2 diabetes mellitus]
Soto N, Alcaraz A, Pichon-Riviere A, Augustovski F, García Martí S, Bardach A, Ciapponi A.
Record ID 32018001387
Spanish
Original Title:
Tiazolidinedionas para tratamiendo de diabetes mellitus tipo 2
Authors' recommendations:
CONCLUSIONS
High quality evidence shows that thiazolidinediones (rosiglitazone and pioglitazone) are efficacious in providing some kind of glucose control to type 2 diabetic patients. Adding these drugs to metformin therapy would reduce HbA1c by 1%, just like other oral antidiabetic agents. As regards safety, the use of rosiglitazone is associated to cardiovascular adverse effects such as heart failure when combined with insulin, and the use of pioglitazone is associated to a higher incidence of bladder cancer. Both drugs are associated to an increase in the incidence of bone fractures. Some European regulatory agencies do not approve their use given their safety profile.
The clinical practice guidelines consulted include them as a treatment option, in combination with metformin or other oral antidiabetic drugs or as monotherapy when metformin cannot be used.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Diabetes Mellitus, Type 2
- Thiazolidinediones
- Drug Therapy
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.